Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study

Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that patient
enrollment to the Phase II clinical trial for TASQ, a novel compound
for the treatment of prostate cancer, is completed after enrollment
of 200 patients into the study, according to the clinical protocol.

The study is a 2:1 randomized, placebo-controlled, double-blind Phase
II study  of 1  mg/day  TASQ versus  placebo. The  study  encompasses
symptom-free patients  with metastatic,  hormone-resistant,  prostate
cancer.

The primary endpoint of the study is to measure the proportion of
patients that do not display disease progression after six months of
TASQ therapy compared with placebo. Secondary clinical endpoints of
importance for this group of patients include time to clinical
progression, safety and to measure changes in PSA (Prostate Specific
Antigen) blood levels. Documentation of such endpoints is of
importance for future TASQ development and registration.

Results from this study are expected by the end of 2009/beginning of
2010.



Lund den 8 June 2009
Active Biotech AB (publ)

Tomas Leanderson
President  & CEO



About TASQ
The development of TASQ  is principally focused  on the treatment  of
prostate cancer. TASQ is an antiangiogenic compound, meaning that  it
cuts off the supply of nutrients to the tumor and does not belong  to
the most frequently  occurring group of  tyrosine kinase  inhibitors.
Positive results for the  concluded Phase I trial  show that TASQ  is
well-tolerated and has a favorable safety profile. In September 2008,
the follow-up  efficacy data  from the  Phase Ib  trial of  TASQ  was
presented.  Patients  treated  with  TASQ  developed  few  new   bone
metastases and displayed a  reduced rate of  increase of the  disease
marker PSA (Prostate-Specific Antigen). For further information, view
the presentation from the UBS Global Life Sciences conference. Within
this project, a placebo-controlled Phase II trial is being  performed
in the  US,  Canada and  Sweden.  In February  2009,  an  independent
international expert group,  a Data Safety  Monitoring Board  (DSMB),
evaluated the ongoing clinical Phase II trial of TASQ. The board  had
access to  the study's  unblinded safety  data and  studied the  side
effect profile  of TASQ.  After analyzing  long-term data  concerning
more than 50 patients  treated with TASQ,  DSMB recommended that  the
trial  continue  in   accordance  with   the  established   protocol.
Information  about  the  ongoing  clinical  trial  is  available   at
www.activebiotech.com and www.clinicaltrials.gov.


About Active Biotech
Active Biotech  AB  (NASDAQ  OMX NORDIC:  ACTI)  is  a  biotechnology
company with focus  on autoimmune/inflammatory  diseases and  cancer.
Projects in  pivotal phase  are  laquinimod, an  orally  administered
small  molecule  with  unique  immunomodulatory  properties  for  the
treatment of multiple sclerosis, as well as ANYARA for use in  cancer
targeted therapy, primarily of renal cancer. Further key projects  in
clinical development comprise the three orally administered compounds
TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please
visit www.activebiotech.com for more information.


Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is required under  the Securities Markets Act to  make
the information in  this press  release public.  The information  was
submitted for publication at 08:30 am CET on June 8, 2009.